Add this topic to your myFT Digest for news straight to your inbox
Merck pulls ahead in race for new generation of cancer treatments
Flotations stall due to fears over economic outlook and mispricing
Study finds US group’s Opdivo cancer drug is inferior to chemotherapy
Opdivo had been tipped as a replacement for chemotherapy for many patients
Doctors and investors predict shift in fortunes after Bristol-Myers’ immunotherapy trial fails
US stocks lack direction after post-payrolls record
Clinical trial shock deals $23bn blow to hopes for blockbuster immunotherapy treatment
Many experts believe a new type of drug promises to revolutionise treatment
Immunotherapy results ‘very positive’, says Asco president Julie Vose
Drugmaker to test new therapy designed to turn immune system into a weapon against tumours
The big-company veteran on raising funds and hiring for a biotech start-up
SalvaRX working on treatments using T-cells to attack tumours
US drugmaker ends ‘initiatives’ aimed at boosting sales in second-largest pharmaceuticals market
Sprawling business models of the largest groups come under the microscope
Falling number of potential patients and competition from Merck pose threats
Cost watchdog says treatment is good value for money
UK group will buy late-stage experimental therapies as record year for pharma M&A draws to a close
Olivier Brandicourt lamented mis-steps left group absent from important new category of cancer drugs
International Edition